NIH: Low Threat from Avian Flu H5N1
The highly pathogenic avian influenza H5N1 virus (HPAI H5N1) continues to pose a low risk to the general public, and health experts in the United States anticipate that available and developing treatments and vaccines will be sufficient to prevent severe illness. However, the National Institutes of Health (NIH) and its federal partners continue to focus on monitoring the virus and assessing changes, according to leaders at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. In a commentary published in The New England Journal of Medicine, NIAID Director Jeanne M. Marrazzo, MD, MPH, and Michael G. Ison, MD, MS, chief of the Respiratory Diseases Division in NIAID’s Division of Microbiology and Infectious Diseases, explain that a balance should be struck between increased vigilance and “business as usual” regarding HPAI H5N1. Since 1996, HPAI…


